43.11
+1.32(+3.16%)
Currency In CNY
Address
Building 2 Room 105, No. 230 Cailun RoadChina (Shanghai) Pilot Free Trade Zone Shanghai, 201210China
Shanghai, 201210
China
Phone
86 21 5833 2260
Website
Sector
Healthcare
Industry
Biotechnology
Employees
1416
First IPO Date
January 18, 2022
| Name | Title | Pay | Year Born |
| Dr. Datao Liu Ph.D. | Chairman, Chief Executive Officer & GM | 0 | 1972 |
| Dr. Hai Wu Ph.D. | Deputy GM, President of R&D and Director | 0 | 1974 |
| Dr. Xun Gui | Vice President, Deputy GM & Director | 0 | N/A |
| Ms. Xi Chen | Deputy General Manager | 0 | 1980 |
| Mr. Jun Hua | Vice President, Chief Financial Officer & Deputy GM | 0 | 1981 |
| Dr. Xin Du Ph.D. | Chief Scientific Officer & President of Maiwei (US) | 0 | 1972 |
| Dr. Yinhan Guo Ph.D. | Chief Development Officer | 0 | 1971 |
| Mr. Shu Hai Wang Ph.D. | Senior Vice President & CMO | 0 | 1974 |
| Mr. Huiguo Hu | Senior Vice President, CCO, Secretary of the Board & Director | 0 | 1977 |
| Mr. Jinchao Zhang | Deputy General Manager | 0 | 1972 |
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of biological products in China and internationally. The company offers its products for auto-immune, oncology, ophthalmologic, and infectious diseases, as well as metabolic disorders, etc. It offers JUNMAIKANG, an autoimmune Adalimumab injection. The company’s oncology products pipeline includes 9MW2821 and 6MW3211, which are in phase II of clinical trial; 9MW2921, 9MW3811, and 7MW3711, which are in phase I clinical trials; 9MW0321; and 8MW0511, which is in phase III clinical trial. It also develops autoimmune products, such as 9MW1911 and 9MW3811, which are in phase 1 clinical trial; metabolic products comprising MAILISHU and 9MW3011; ophthalmology candidates, including 9MW0813 and 9MW0211 that are in phase III clinical trial; and 9MW1411, an infectious product candidate. The company was founded in 2017 and is based in Shanghai, China.
